Inocrave 15 & 30 15 mg, 30 mg Capsule
PDF Leaflet Revision Date: 26 September 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Management of obesity as part of a comprehensive weight reduction regimen.
Dosage (summary)
One capsule daily at approximately 7 a.m. for adults and children over 12 years.
Onset of Action / Duration
Onset: 10-14 hours, Duration: up to 3 months
Special Populations
- Renal impairment
- Mild hypertension
- Established coronary artery disease
Pregnancy & Breastfeeding
Not recommended in pregnancy or lactation due to safety concerns.
Key Drug Interactions
- MAO inhibitors
- Sympathomimetics
- Thyroid hormones
- Alcohol
Contraindications
- Pulmonary artery hypertension
- Cardiac disease
- Hyperthyroidism
- Glaucoma
- History of drug/alcohol abuse
Common side effects
- Insomnia
- Dizziness
- Tachycardia
- Dry mouth
- Nausea
Counselling Points
- Avoid evening dosing to prevent insomnia
- Monitor for cardiovascular symptoms
- Do not combine with other appetite suppressants
Serious warnings
- Risk of primary pulmonary hypertension
- Valvular heart disease
- Caution in patients with hypertension
Important Disclaimer
The Inocrave 15 & 30 15 mg, 30 mg Capsule professional information leaflet below is the property of Inova Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
